WhiteSwell, a Galway, Ireland-based company advancing new ways to treat acute decompensated heart failure, closed a $30m series B funding.
The round was led by RA Capital Management and an InCube Ventures syndicate, with participation from other investors.
The company intends to use the funds for product development and a pivotal study of its innovative technology for the treatment of acute decompensated heart failure (ADHF).
Founded by chief technology officer Yaacov Nitzan in 2014, and also led by chief executive officer Eamon Brady and chief financial officer Seán Mac Réamoinn, WhiteSwell is dedicated to improving treatment of acute decompensated heart failure (ADHF), a primary cause of repeat hospitalization and emergency room visits. The company is advancing a minimally invasive catheter-based approach designed to more remove excess interstitial fluid in patients with ADHF by enhancing the natural fluid removal process of the lymphatic system.
WhiteSwell is currently conducting an early feasibility study at clinical sites in the U.S., Israel and Europe.